Aynura Rustamzada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aynura Rustamzada has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Bilger Çavuş
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
4 shared publications - Aslı Çifcibaşı Örmeci
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
2 shared publications - Fatih Beşışık
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
2 shared publications - Kadir Demir
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
2 shared publications - Pelin Telli
Istanbul University
2 shared publications - Sabahattin Kaymakoglu
Division of Gastroenterohepatology, Department of Internal Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye
2 shared publications
Latest Publications
- 15 May 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (4) , 479-486
Time of first diagnosis in liver cirrhosis: what has changed over time from etiology to stage of disease?
It was aimed to investigate the characteristics of cirrhosis etiology, stage at diagnosis, diagnostic methods, and complications with a 1-decade interval. The clinical and demographic characteristics of patients with cirrhosis at the time of diagnosis at a tertiary university hospital between 2005-2009 (first period) and 2019-2023 (second period) were retrospectively investigated. In total, 1311 patients were diagnosed with cirrhosis, of which 857 (65.4%) were men. Seven hundred and ninety-eight (60.9%) were diagnosed in the first period. Six hundred and ninety (52.6%) patients were decompensated at diagnosis. Child Turcotte Pugh score was more common in the second period. MELD-Na score was higher in the first period (p = 0.026). The presentation rate with decompensation was higher in the first period (p = 0.009). In the first period, 211 (26.4%), and in the second period, 134 (26.1%) patients were diagnosed in the emergency department. The others were diagnosed in the outpatient clinic. There was no difference in the conditions for diagnosing between periods (p = 0.898). The causes of cirrhosis were, in order, 22.6% HBV, 19.7% MASLD, 18.9% cryptogenic, 13.1% ALD, 10.1% HCV, 7.7% autoimmune liver diseases, 4% HDV, 2.1% other causes, and 1.8% genetic diseases. In the second period, the frequency of cirrhosis caused by viral etiologies decreased (p < 0.05), and the frequency of MASLD and ALD increased (p < 0.05). Over the past decade, viral factors in the etiology of cirrhosis have gradually decreased, MASLD and ALD have progressively increased. While patients were detected more in compensated states, a significant portion of patients are still diagnosed in the decompensated stage and in emergency clinics.
- 15 May 2026
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 138 (4) , 479-486
Time of first diagnosis in liver cirrhosis: what has changed over time from etiology to stage of disease?
It was aimed to investigate the characteristics of cirrhosis etiology, stage at diagnosis, diagnostic methods, and complications with a 1-decade interval. The clinical and demographic characteristics of patients with cirrhosis at the time of diagnosis at a tertiary university hospital between 2005-2009 (first period) and 2019-2023 (second period) were retrospectively investigated. In total, 1311 patients were diagnosed with cirrhosis, of which 857 (65.4%) were men. Seven hundred and ninety-eight (60.9%) were diagnosed in the first period. Six hundred and ninety (52.6%) patients were decompensated at diagnosis. Child Turcotte Pugh score was more common in the second period. MELD-Na score was higher in the first period (p = 0.026). The presentation rate with decompensation was higher in the first period (p = 0.009). In the first period, 211 (26.4%), and in the second period, 134 (26.1%) patients were diagnosed in the emergency department. The others were diagnosed in the outpatient clinic. There was no difference in the conditions for diagnosing between periods (p = 0.898). The causes of cirrhosis were, in order, 22.6% HBV, 19.7% MASLD, 18.9% cryptogenic, 13.1% ALD, 10.1% HCV, 7.7% autoimmune liver diseases, 4% HDV, 2.1% other causes, and 1.8% genetic diseases. In the second period, the frequency of cirrhosis caused by viral etiologies decreased (p < 0.05), and the frequency of MASLD and ALD increased (p < 0.05). Over the past decade, viral factors in the etiology of cirrhosis have gradually decreased, MASLD and ALD have progressively increased. While patients were detected more in compensated states, a significant portion of patients are still diagnosed in the decompensated stage and in emergency clinics.
- 11 February 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (5) , 820-829
Liver Fibrosis and Steatosis in Inflammatory Bowel Disease: A Cross‐Sectional Matched‐Control Transient Elastography Study (ELASTIBD)
Aim: Metabolic dysfunction‐associated steatotic liver disease (MASLD) and liver fibrosis are emerging extraintestinal manifestations of inflammatory bowel disease (IBD), but their true burden and the impact of therapies on liver health have not been fully elucidated. We aimed to assess the prevalence of hepatic steatosis and fibrosis in IBD versus matched controls and examine associations with therapies, particularly anti‐TNF agents and corticosteroids. Methods: In this cross‐sectional study, 358 adults with IBD and 358 controls individually matched for age, sex, BMI, and diabetes underwent vibration‐controlled transient elastography (VCTE; FibroScan). These are the baseline findings of the ongoing ELASTIBD cohort. Results: Patients with IBD had higher rates of significant fibrosis (12.3% vs. 4.2%; adjusted odds ratio [aOR] 3.31 and 95% CI 1.75–6.26), advanced fibrosis (6.7% vs. 0.6%; OR 8.50 and 95% CI 1.98–36.52), and steatosis (41.4% vs. 28.3%; aOR 2.51 and 95% CI 1.66–3.79) than controls. Among patients with IBD, anti‐TNF therapy was less frequent in those with fibrosis (44.4% vs. 68.5% and p = 0.004) and independently associated with lower odds of fibrosis (aOR 0.39 and 95% CI 0.16–0.95), whereas each steroid course was associated with 41% higher odds (aOR 1.41 and 95% CI 1.04–1.92). Older age and higher BMI were additional predictors. Conclusions: Patients with IBD demonstrated threefold higher fibrosis and twofold higher steatosis than matched controls, emphasizing the importance of liver assessment in clinical practice. The inverse association between anti‐TNF exposure and fibrosis suggests inflammation control may reduce hepatic fibrogenesis and supports follow‐up of the ELASTIBD cohort to clarify progression, treatment effects, and liver outcomes.
- 11 February 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (5) , 820-829
Liver Fibrosis and Steatosis in Inflammatory Bowel Disease: A Cross‐Sectional Matched‐Control Transient Elastography Study (ELASTIBD)
Aim: Metabolic dysfunction‐associated steatotic liver disease (MASLD) and liver fibrosis are emerging extraintestinal manifestations of inflammatory bowel disease (IBD), but their true burden and the impact of therapies on liver health have not been fully elucidated. We aimed to assess the prevalence of hepatic steatosis and fibrosis in IBD versus matched controls and examine associations with therapies, particularly anti‐TNF agents and corticosteroids. Methods: In this cross‐sectional study, 358 adults with IBD and 358 controls individually matched for age, sex, BMI, and diabetes underwent vibration‐controlled transient elastography (VCTE; FibroScan). These are the baseline findings of the ongoing ELASTIBD cohort. Results: Patients with IBD had higher rates of significant fibrosis (12.3% vs. 4.2%; adjusted odds ratio [aOR] 3.31 and 95% CI 1.75–6.26), advanced fibrosis (6.7% vs. 0.6%; OR 8.50 and 95% CI 1.98–36.52), and steatosis (41.4% vs. 28.3%; aOR 2.51 and 95% CI 1.66–3.79) than controls. Among patients with IBD, anti‐TNF therapy was less frequent in those with fibrosis (44.4% vs. 68.5% and p = 0.004) and independently associated with lower odds of fibrosis (aOR 0.39 and 95% CI 0.16–0.95), whereas each steroid course was associated with 41% higher odds (aOR 1.41 and 95% CI 1.04–1.92). Older age and higher BMI were additional predictors. Conclusions: Patients with IBD demonstrated threefold higher fibrosis and twofold higher steatosis than matched controls, emphasizing the importance of liver assessment in clinical practice. The inverse association between anti‐TNF exposure and fibrosis suggests inflammation control may reduce hepatic fibrogenesis and supports follow‐up of the ELASTIBD cohort to clarify progression, treatment effects, and liver outcomes.
- Open Access
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 846-854
What are the predictors of malignancy in inflammatory bowel disease?
Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system. Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05). Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 846-854
Open AccessWhat are the predictors of malignancy in inflammatory bowel disease?
Background/aimː This study aims to investigate the prevalence of malignancy in patients with inflammatory bowel disease (IBD) followed up in a tertiary reference center. Materials and methodsː IBD patients with at least 6 months of follow-up from the gastroenterology clinic between 2000 and 2022 wereevaluated retrospectively in a tertiary center. Patient information was obtained from the patient registration system. Resultsː There were 697 patients in the study, 320 (45.9%) of these were female. The mean age of the patients at IBD diagnosis was 33.4± 13.1 years. The mean follow-up time was 93.1 ± 64.8 (median 84, IQR (25–75) (36–144)) months. IBD types were as; 315 (45.2%) hadulcerative colitis, and 382 (54.8%) had Crohn’s disease. Before the diagnosis of IBD, 10 patients (1.4%) had a history of malignancy. Theprevalence of malignancy after the diagnosis of IBD was 13 (1.9%). There was a relationship between malignancy and older age, higherBMI, and female sex in survival analysis (p < 0.05). There was no correlation with disease type and malignancy (p = 0.820). When thepatients who developed malignancy in IBD were compared in terms of the immunomodulators and biological agents used by the patients who did not develop malignancy, there was no statistical difference between the two groups (p > 0.05). Conclusionː Older age, higher BMI, and female sex were found to be at risk for the development of malignancy in IBD, although norelationship was found with the use of immunomodulators, biological agents, or disease type.
- 21 July 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (3) , 296-297
The Lactulose Breath Test can Predict Refractory Gastroesophageal Reflux Disease by Measuring Bacterial Overgrowth in the Small Intestine
- 21 July 2025
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 60 (3) , 296-297
The Lactulose Breath Test can Predict Refractory Gastroesophageal Reflux Disease by Measuring Bacterial Overgrowth in the Small Intestine